A subscription to JoVE is required to view this content. Sign in or start your free trial.
There is a need to determine which atherosclerotic lesions will progress in the coronary vasculature to guide intervention before myocardial infarction occurs. This article outlines the biomechanical modeling of arteries from Optical Coherence Tomography using fluid-structure interaction techniques in a commercial finite element solver to help predict this progression.
In this paper, we present a complete workflow for the biomechanical analysis of atherosclerotic plaque in the coronary vasculature. With atherosclerosis as one of the leading causes of global death, morbidity and economic burden, novel ways of analyzing and predicting its progression are needed. One such computational method is the use of fluid-structure interaction (FSI) to analyze the interaction between the blood flow and artery/plaque domains. Coupled with in vivo imaging, this approach could be tailored to each patient, assisting in differentiating between stable and unstable plaques. We outline the three-dimensional reconstruction process, making use of intravascular Optical Coherence Tomography (OCT) and invasive coronary angiography (ICA). The extraction of boundary conditions for the simulation, including replicating the three-dimensional motion of the artery, is discussed before the setup and analysis is conducted in a commercial finite element solver. The procedure for describing the highly nonlinear hyperelastic properties of the artery wall and the pulsatile blood velocity/pressure is outlined along with setting up the system coupling between the two domains. We demonstrate the procedure by analyzing a non-culprit, mildly stenotic, lipid-rich plaque in a patient following myocardial infarction. Established and emerging markers related to atherosclerotic plaque progression, such as wall shear stress and local normalized helicity, respectively, are discussed and related to the structural response in the artery wall and plaque. Finally, we translate the results to potential clinical relevance, discuss limitations, and outline areas for further development. The method described in this paper shows promise for aiding in the determination of sites at risk of atherosclerotic progression and, hence, could assist in managing the significant death, morbidity, and economic burden of atherosclerosis.
Coronary artery disease (CAD) is the most common type of heart disease and one of the leading causes of death and economic burden globally1,2. In the United States, roughly one in every eight deaths is attributed to CAD3,4, while most global deaths from CAD are now seen in low- and middle-income countries5. Atherosclerosis is the predominant driver of these deaths, with plaque rupture or erosion leading to coronary artery occlusion and acute myocardial infarction (AMI)6. Even after revascularization of culprit coronary lesions, patients have substantial risk of recurrent major adverse cardiovascular events (MACE) after AMI, largely due to the concomitant presence of other non-culprit plaques that are also vulnerable to rupture7. Intracoronary imaging provides an opportunity to detect these high-risk plaques8. Although intravascular ultrasound (IVUS) is the gold standard for evaluating plaque volume, it has limited resolution to identify microstructural features of vulnerable plaque in contrast to the high resolution (10-20 µm) of optical coherence tomography (OCT). A thin and inflamed fibrous cap overlying a large lipid pool has been demonstrated to be the most important signature of a vulnerable plaque9 and is best identified and measured by OCT among currently available intracoronary imaging modalities10. Importantly, OCT is also able to assess other high-risk plaque features, including: lipid arc; macrophage infiltration; presence of thin cap fibroatheroma (TCFA), which is defined as lipid-rich core with overlying thin fibrous cap (<65 µm); spotty calcification; and plaque microchannels. OCT detection of these high-risk features in non-culprit plaques post-AMI has been associated with up to a 6-fold increased risk of future MACE11. However, despite this, the ability of angiography and OCT imaging to predict which coronary plaques will progress and ultimately rupture or erode is limited, with positive predictive values of only 20%-30%8. This limited predictive ability hinders clinical decision-making around which non-culprit plaques to treat (e.g., by stenting)7,12.
In addition to patient factors and the biological characteristics of plaque, biomechanical forces in the coronary arteries are also important determinants of plaque progression and instability13. One technique that shows promise for helping to comprehensively evaluate these forces is fluid-structure interaction (FSI)14 simulation. Wall shear stress (WSS), also called endothelial shear stress, has been a traditional focal point for coronary biomechanics research15, with a general understanding that WSS plays an etiological role in atherosclerosis formation16. Predominantly simulated using computational fluid dynamics (CFD) techniques, low WSS regions have been associated with intimal thickening17, vascular remodeling18 and the prediction of lesion progression19 and future MACE20. Recent advances in these analyses suggest the underlying WSS vector field topology21, and its multidirectional characteristics22, as a better predictor of atherosclerosis risk than WSS magnitude alone. However, WSS only captures a glimpse of the overall biomechanical system at the lumen wall, and much like imaging modalities, no one biomechanical metric can reliably discern high risk atherosclerotic features.
Further metrics are emerging as potentially important in atherosclerosis formation. Intraluminal flow characteristics23 are one such example, with helical flow, quantified through various indices24, suggested as playing an atheroprotective role by suppressing disturbed flow patterns25,26. While CFD techniques can analyze these flow characteristics and present a wide range of useful results, they do not consider the underlying interactions between the blood flow, artery structure and general heart motion. This simplification of the dynamic system to a rigid wall misses potentially critical results such as fibrous cap stress. While the debate both for and against the need for FSI over CFD continues27,28,29, many comparisons neglect to include the impact of ventricle function. This limitation can be overcome with FSI, which has shown that dynamic bending and compression exerted on the artery through the influence of the ventricle function can significantly impact plaque and artery structural stress as well as flow metrics such as WSS30,31,32. This is important as structural stresses are also a key metric for analyzing and predicting plaque rupture33,34 and have been suggested to co-locate with regions of plaque increase14,35. Capturing these interactions allows for a more realistic representation of the coronary environment and the potential mechanisms of disease progression.
Addressing this, here we outline the process of developing a patient-specific geometry from OCT imaging36 and the setting up and running of an artery FSI simulation using a commercial finite element solver. The process to manually extract the lumen, lipid and outer artery wall is detailed before the three-dimensional computational reconstruction of the patient's artery. We outline the simulation set-up, coupling and the process of comparing baseline, and follow-up OCT imaging parameters to determine lesion progression. Finally, we discuss the post-processing of numerical results and how these data may have clinical relevance by comparing the biomechanical results with lesion progression/regression. The overall method is demonstrated on non-culprit, mildly stenotic, lipid-rich plaques in the right coronary artery (RCA) of a 58-year-old Caucasian male patient who presented with an acute non-ST elevation myocardial infarction in the setting of hypertension, type 2 diabetes mellitus, obesity (BMI 32.6) and a family history of premature CAD. Coronary angiography and OCT imaging were performed during his initial admission, and then 12 months later as part of an ongoing clinical trial (COCOMO-ACS trial ACTRN12618000809235). We anticipate that this technique can be further refined and used for identifying coronary plaques that are at high risk of progressing.
The following deidentified data was analyzed from a patient recruited into the ongoing COCOMO-ACS randomized-controlled trial (ACTRN12618000809235; Royal Adelaide Hospital HREC reference number: HREC/17/RAH/366), with additional ethics approval granted by Central Adelaide Local Health Network (CALHN) Research Services for the purpose of biomechanical simulation (CALHN Reference Number 14179). Figure 1 summarizes the complete workflow outlined in the following protocol, which can be applied to any FSI capable software or codes.
1. Image evaluation
2. Three-dimensional reconstruction
3. Artery/structural
4. Blood/fluid
5. System coupling
Representative results are presented for both established and emerging biomechanical markers of atherosclerosis progression. Established metrics such as WSS and WSS-derived results (including time averaged wall shear stress (TAWSS) and oscillatory shear index (OSI)) are visualized in Figure 10. The wall shear stress over the cardiac cycle is largely driven by the blood velocity, however, artery geometry and its motion/contraction play a significant role in its spatial distribution. This can ...
The use of FSI methods to analyze coronary biomechanics is still a developing field from both numerical modelling and clinical result aspects. Here we have described the outline of setting up a patient specific FSI analysis, based on the finite element/finite volume methods, utilizing OCT and angiographic imaging. While the method we describe here utilizes a commercial finite element solver, the procedure can be applied to any FSI capable software. There are still several limitations to be improved upon in the methodolog...
The authors have no conflicts to declare regarding the preparation of this article. S.J.N. has received research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and Liposcience and is a consultant for AstraZeneca, Akcea, Eli Lilly, Anthera, Kowa, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, and Boehringer Ingelheim. P.J.P. has received research support from Abbott Vascular, consulting fees from Amgen and Esperion and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Schering-Plough, and Pfizer.
The authors would like to acknowledge the support provided by The University of Adelaide, Royal Adelaide Hospital (RAH) and the South Australian Health and Medical Research Institute (SAHMRI). The COCOMO-ACS trial is an investigator-initiated study funded by project grants from the National Health and Medical Research Council (NHMRC) of Australia (ID1127159) and National Heart Foundation of Australia (ID101370). H.J.C. is supported by a scholarship from the Westpac Scholars Trust (Future Leaders Scholarship) and acknowledges support from The University of Adelaide, School of Mechanical Engineering and the Department of Education, Skills and Employment Research Training Program (RTP) scholarship. S.J.N. receives a Principal Research Fellowship from the NHMRC (ID1111630). P.J.P. receives a Level 2 Future Leader Fellowship from the National Heart Foundation of Australia (FLF102056) and Level 2 Career Development Fellowship from the NHMRC (CDF1161506).
Name | Company | Catalog Number | Comments |
ANSYS Workbench (version 19.0) | ANSYS | Commercial finite element solver | |
MATLAB (version 2019b) | Mathworks | Commercial programming platform | |
MicroDicom/ImageJ | MicroDicom/ImageJ | Open Source DICOM reader | |
Visual Studio (version 2019) | Microsoft | Commercial Integrated Development Environment |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved